199 related articles for article (PubMed ID: 22571507)
21. Low-dose amphotericin B lipid complex vs. conventional amphotericin B for empirical antifungal therapy of neutropenic fever in patients with hematologic malignancies--a randomized, controlled trial.
Subirà M; Martino R; Gómez L; Martí JM; Estany C; Sierra J
Eur J Haematol; 2004 May; 72(5):342-7. PubMed ID: 15059069
[TBL] [Abstract][Full Text] [Related]
22. Fluconazole versus amphotericin B as empirical antifungal therapy of unexplained fever in granulocytopenic cancer patients: a pragmatic, multicentre, prospective and randomised clinical trial.
Viscoli C; Castagnola E; Van Lint MT; Moroni C; Garaventa A; Rossi MR; Fanci R; Menichetti F; Caselli D; Giacchino M; Congiu M
Eur J Cancer; 1996 May; 32A(5):814-20. PubMed ID: 9081359
[TBL] [Abstract][Full Text] [Related]
23. Liposomal amphotericin B for prophylaxis of invasive fungal infections in high-risk paediatric patients with chemotherapy-related neutropenia: interim analysis of a prospective study.
Uhlenbrock S; Zimmermann M; Fegeler W; Jürgens H; Ritter J
Mycoses; 2001 Dec; 44(11-12):455-63. PubMed ID: 11820258
[TBL] [Abstract][Full Text] [Related]
24. A prospective, randomized multicenter trial of the empirical addition of antifungal therapy for febrile neutropenic cancer patients: results of the Paul Ehrlich Society for Chemotherapy (PEG) Multicenter Trial II.
Schiel X; Link H; Maschmeyer G; Glass B; Cornely OA; Buchheidt D; Wilhelm M; Silling G; Helmerking M; Hiddemann W; Ostermann H; Hentrich M
Infection; 2006 Jun; 34(3):118-26. PubMed ID: 16804654
[TBL] [Abstract][Full Text] [Related]
25. Intravenous and oral itraconazole versus intravenous amphotericin B deoxycholate as empirical antifungal therapy for persistent fever in neutropenic patients with cancer who are receiving broad-spectrum antibacterial therapy. A randomized, controlled trial.
Boogaerts M; Winston DJ; Bow EJ; Garber G; Reboli AC; Schwarer AP; Novitzky N; Boehme A; Chwetzoff E; De Beule K;
Ann Intern Med; 2001 Sep; 135(6):412-22. PubMed ID: 11560454
[TBL] [Abstract][Full Text] [Related]
26. Caspofungin versus liposomal amphotericin B for empirical therapy.
Jones BL; McLintock LA
N Engl J Med; 2005 Jan; 352(4):410-4; author reply 410-4. PubMed ID: 15675090
[No Abstract] [Full Text] [Related]
27. Economic evaluation of caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia in Sweden.
Naik S; Lundberg J; Kumar R; Sjolin J; Jansen JP
Scand J Infect Dis; 2011 Jul; 43(6-7):504-14. PubMed ID: 21332286
[TBL] [Abstract][Full Text] [Related]
28. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group.
Walsh TJ; Finberg RW; Arndt C; Hiemenz J; Schwartz C; Bodensteiner D; Pappas P; Seibel N; Greenberg RN; Dummer S; Schuster M; Holcenberg JS
N Engl J Med; 1999 Mar; 340(10):764-71. PubMed ID: 10072411
[TBL] [Abstract][Full Text] [Related]
29. Echinocandins versus non-echinocandins for empirical antifungal therapy in patients with hematological disease with febrile neutropenia: A systematic review and meta-analysis.
Yamashita C; Takesue Y; Matsumoto K; Ikegame K; Enoki Y; Uchino M; Miyazaki T; Izumikawa K; Takada T; Okinaka K; Ueda T; Miyazaki Y; Mayumi T
J Infect Chemother; 2020 Jun; 26(6):596-603. PubMed ID: 32171659
[TBL] [Abstract][Full Text] [Related]
30. Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study.
Maertens J; Theunissen K; Verhoef G; Verschakelen J; Lagrou K; Verbeken E; Wilmer A; Verhaegen J; Boogaerts M; Van Eldere J
Clin Infect Dis; 2005 Nov; 41(9):1242-50. PubMed ID: 16206097
[TBL] [Abstract][Full Text] [Related]
31. [Management of febrile neutropenia].
Rolfes N; Lümmen G
Urologe A; 2011 Jul; 50(7):810-2. PubMed ID: 21559914
[TBL] [Abstract][Full Text] [Related]
32. Efficacy and safety of micafungin for treating febrile neutropenia in hematological malignancies.
Goto N; Hara T; Tsurumi H; Ogawa K; Kitagawa J; Kanemura N; Kasahara S; Yamada T; Shimizu M; Nakamura M; Matsuura K; Moriwaki H
Am J Hematol; 2010 Nov; 85(11):872-6. PubMed ID: 20882524
[TBL] [Abstract][Full Text] [Related]
33. Invasive fungal infection in children with persistent febrile neutropenia.
Lai HP; Chen YC; Chang LY; Lu CY; Lee CY; Lin KH; Huang LM
J Formos Med Assoc; 2005 Mar; 104(3):174-9. PubMed ID: 15818431
[TBL] [Abstract][Full Text] [Related]
34. Empiric antifungal therapy in patients with febrile neutropenia.
Ferrara JJ; MacDougall C; Gallagher JC
Pharmacotherapy; 2011 Apr; 31(4):369-85. PubMed ID: 21449626
[TBL] [Abstract][Full Text] [Related]
35. Efficacy of Intravenous Itraconazole Versus Liposomal Amphotericin B as Empirical Antifungal Therapy in Hematological Malignancy with Persistent Fever and Neutropenia: Study Protocol for a Multicenter, Prospective, Randomized Non-inferiority Trial.
Saito AM; Yoshida I; Tanaka S; Sawamura M; Hidaka M; Yoshida S; Uike N; Kaneko Y; Miyazaki Y; Nagai H
Kurume Med J; 2021 Dec; 66(4):239-246. PubMed ID: 34544939
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and safety of micafungin versus intravenous itraconazole as empirical antifungal therapy for febrile neutropenic patients with hematological malignancies: a randomized, controlled, prospective, multicenter study.
Jeong SH; Kim DY; Jang JH; Mun YC; Choi CW; Kim SH; Kim JS; Park JS
Ann Hematol; 2016 Jan; 95(2):337-44. PubMed ID: 26596974
[TBL] [Abstract][Full Text] [Related]
37. Efficacy and safety of caspofungin for the empiric management of fever in neutropenic children.
Koo A; Sung L; Allen U; Naqvi A; Drynan-Arsenault J; Dekker A; Maloney AM; Dupuis LL
Pediatr Infect Dis J; 2007 Sep; 26(9):854-6. PubMed ID: 17721388
[TBL] [Abstract][Full Text] [Related]
38. Pharmacoeconomic evaluation of caspofungin versus liposomal amphotericin B in empirical treatment of invasive fungal infections in Turkey.
Turner SJ; Senol E; Kara A; Al-Badriyeh D; Kong DC; Dinleyici EC
Int J Antimicrob Agents; 2013 Sep; 42(3):276-80. PubMed ID: 23830892
[TBL] [Abstract][Full Text] [Related]
39. Caspofungin versus liposomal amphotericin B for empirical therapy.
Tattevin P; Bareau B; Camus C
N Engl J Med; 2005 Jan; 352(4):410-4; author reply 410-4. PubMed ID: 15675091
[No Abstract] [Full Text] [Related]
40. Micafungin, a novel antifungal agent, as empirical therapy in acute leukemia patients with febrile neutropenia.
Yanada M; Kiyoi H; Murata M; Suzuki M; Iwai M; Yokozawa T; Baba H; Emi N; Naoe T
Intern Med; 2006; 45(5):259-64. PubMed ID: 16595990
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
